articleEMA’s transformative treatments of 202024 February 2021 | By Hannah Balfour (European Pharmaceutical Review)In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
newsLumasiran drug achieves primary and secondary endpoints in Phase III study19 December 2019 | By Victoria Rees (European Pharmaceutical Review)Lumasiran, an investigational drug to treat primary hyperoxaluria type 1, has met its endpoints in clinical trials.